Picture of Alterity Therapeutics logo

ATH — Alterity Therapeutics Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-4.23%
3m-14.54%
6m-31.24%
1yr-35.07%
Volume Change (%)
10d/3m-11.14%
Price vs... (%)
52w High-59.52%
50d MA-8.7%
200d MA-30.6%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value0.99
Price to Tang. Book0.99
Price to Free Cashflown/a
Price to Sales2,644.92
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-37.76%
Return on Equity-35.32%
Operating Margin-100477.7%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Alterity Therapeutics EPS forecast chart

Profile Summary

Alterity Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes. ATH434 has been granted Orphan Drug designation for the treatment of Multiple System Atrophy.

Directors

Last Annual
June 30th, 2021
Last Interim
December 31st, 2021
Incorporated
November 11th, 1997
Public Since
March 27th, 2000
No. of Shareholders
5,867
No. of Employees
11
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
2,406,874,578

ATH Share Price Performance

Upcoming Events for ATH

Q4 2022 Alterity Therapeutics Ltd Earnings Release

Q1 2023 Alterity Therapeutics Ltd Earnings Release

Similar to ATH

Picture of Actinogen Medical logo

Actinogen Medical

au flag iconAustralian Stock Exchange - SEATS

Picture of Adalta logo

Adalta

au flag iconAustralian Stock Exchange - SEATS

Picture of Amplia Therapeutics logo

Amplia Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Anatara Lifesciences logo

Anatara Lifesciences

au flag iconAustralian Stock Exchange - SEATS

Picture of Anteotech logo

Anteotech

au flag iconAustralian Stock Exchange - SEATS

FAQ

Or unlock with your email

Or unlock with your email